Rubraca® (rucaparib) tablets is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

SELECT IMPORTANT SAFETY INFORMATION

Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) occurred in patients exposed to Rubraca, and some cases were fatal. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS/AML is confirmed.

Rubraca can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.

Please see additional Select Important Safety Information throughout this brochure.
Monitor Complete Blood Count (CBC) Testing at Baseline and Monthly Thereafter

For prolonged hematological toxicities (>4 weeks) Interrupt Rubraca or reduce dose and monitor blood counts weekly until recovery

If levels have not recovered to Grade 1 or less after 4 weeks or if MDS/AML is suspected Refer patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics

If MDS/AML is confirmed Discontinue Rubraca

Embryo-fetal toxicity

- Based on its mechanism of action and findings from animal studies, Rubraca can cause fetal harm when administered to a pregnant woman
- Apprise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Rubraca

Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML)

- Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) occur uncommonly in patients treated with Rubraca® (rucaparib) tablets, and are potentially fatal adverse reactions. In approximately 1100 treated patients, MDS/AML occurred in 12 patients (1.1%), including those in long term follow-up. Of these, 5 occurred during treatment or during the 28 day safety follow-up (0.5%). The duration of Rubraca treatment prior to the diagnosis of MDS/AML ranged from 1 month to approximately 28 months. The cases were typical of secondary MDS/cancer therapy-related AML; in all cases, patients had received previous platinum-containing regimens and/or other DNA damaging agents.

- Do not start Rubraca until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1)

Monitoring guidance
Dosing for maintenance therapy

**Recommended dose of Rubraca**
Rubraca® (rucaparib) tablets recommended starting dose is 600 mg BID—two 300 mg tablets taken orally twice daily with or without food.¹

- Doses should be taken approximately 12 hours apart
- Rubraca tablets can be taken with or without food
- Continue treatment until disease progression or unacceptable toxicity
- If a patient misses a dose, instruct the patient to take the next dose at its scheduled time
- Vomited doses should not be replaced

**Overdosage¹**
- There is no specific treatment in the event of Rubraca overdose, and symptoms of overdose are not established
  - In the event of suspected overdose, physicians should follow general supportive measures and should treat symptomatically

**Storage and handling¹**
- Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)

**Recommended dose adjustments**

<table>
<thead>
<tr>
<th>Dose Reductions</th>
<th>Dose</th>
<th>Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting dose</td>
<td>600 mg twice daily</td>
<td><img src="image" alt="600mg-300mg-300mg" /></td>
</tr>
<tr>
<td>First dose reduction</td>
<td>500 mg twice daily</td>
<td><img src="image" alt="500mg-250mg-250mg" /></td>
</tr>
<tr>
<td>Second dose reduction</td>
<td>400 mg twice daily</td>
<td><img src="image" alt="400mg-200mg-200mg" /></td>
</tr>
<tr>
<td>Third dose reduction</td>
<td>300 mg twice daily</td>
<td><img src="image" alt="300mg-300mg" /></td>
</tr>
</tbody>
</table>

- Dose interruptions and reductions may be used to manage adverse reactions

**Rubraca is available in 3 dosing strengths to allow for flexibility of dosing¹**

- 300 mg: Supplied in bottles of 60 tablets (NDC: 69660-203-91)
- 250 mg: Supplied in bottles of 60 tablets (NDC: 69660-202-91)
- 200 mg: Supplied in bottles of 60 tablets (NDC: 69660-201-91)

Images do not reflect actual size of each tablet.
Adverse reactions reported in the phase 3 ARIEL3 trial of Rubraca as maintenance therapy

This table includes adverse reactions that occurred in ≥20% of patients treated with Rubraca® (rucaparib) tablets.

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Rubraca (n=372)</th>
<th>Placebo (n=189)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grades 1-4 (%)</td>
<td>Grades 3-4 (%)</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>76</td>
<td>4</td>
</tr>
<tr>
<td>Abdominal pain/distention†</td>
<td>46</td>
<td>3</td>
</tr>
<tr>
<td>Constipation</td>
<td>37</td>
<td>2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>37</td>
<td>4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>32</td>
<td>0.5</td>
</tr>
<tr>
<td>Stomatitis†</td>
<td>28</td>
<td>1</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue/asthenia</td>
<td>73</td>
<td>7</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash†</td>
<td>43</td>
<td>1</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyseusia</td>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST/ALT elevation</td>
<td>38</td>
<td>11</td>
</tr>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>39</td>
<td>21</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>29</td>
<td>5</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>20</td>
<td>8</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic, and mediastinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis/upper respiratory tract infection†</td>
<td>29</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>23</td>
<td>1</td>
</tr>
</tbody>
</table>

*National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

†Consists of grouped related terms that reflect the medical concept of the adverse reaction.

- Adverse reactions occurring in <20% of patients treated with Rubraca included headache, dizziness, dyspepsia, insomnia, dyspnea, pyrexia, peripheral edema, and depression†

Please see Select Important Safety Information throughout this brochure.
Elevations in ALT or AST concentrations were generally transient, self-limiting, and not associated with other signs of liver toxicity. These increases generally stabilized over time.

No apparent pharmacokinetic differences were observed in patients with mild hepatic impairment who received Rubraca® (rucaparib) tablets 600 mg twice daily compared to patients with normal hepatic function.

The following guidance was established in clinical trials for patients with Grade 3 and 4 ALT/AST elevations:

### ARIEL3 Monitoring and Management Recommendations for ALT/AST Elevations

| Grade 3 elevations without any other signs of liver dysfunction | Monitor liver function tests weekly until ≤Grade 2
| - Continue treatment as long as bilirubin is <ULN and alkaline phosphatase is <3 x ULN
| - If levels do not decline within 2 weeks or continue to rise, interrupt treatment
| - If resolved to ≤Grade 2, resume treatment, either at same or reduced dose |
| Grade 4 elevations | Withhold treatment until return to ≤Grade 2
| - If resolved to ≤Grade 2, resume at a reduced dose and monitor liver function weekly for 3 weeks after restarting treatment |

2/371 patients (<1%) discontinued Rubraca due to ALT/AST elevations.

---

- Horizontal dotted lines in graph represent the upper and lower limits of normal.
- Cycle=28 days. With the exception of Cycle 1, each number on the x axis represents Day 1 of that cycle.
- Mild hepatic impairment was defined as total bilirubin ≤ULN and AST >ULN, or total bilirubin between 1.0-1.5 times ULN and any AST.
- SEM=standard error of the mean; ULN=upper limit of normal.
Laboratory abnormalities: hemoglobin & platelets

Mean hemoglobin levels reported in ARIEL3\textsuperscript{1,3*}

![Graph showing mean hemoglobin levels reported in ARIEL3 for patients treated with Rubraca and Placebo.]

- 139/372 patients (37%) receiving Rubraca\textsuperscript{®} (rucaparib) tablets and 11/189 patients (6%) receiving placebo experienced anemia/low or decreased hemoglobin; median time to onset was 2 months and 1 month, respectively\textsuperscript{2,4}
- Most of the anemia-related adverse reactions were managed with dose reductions or interruptions, hematopoietic growth factors,\textsuperscript{4} and blood transfusions\textsuperscript{4}
- Anemia/low or decreased hemoglobin led to dose discontinuations in 11/372 of patients (3%)\textsuperscript{1}

Mean platelet levels reported in ARIEL3\textsuperscript{1,3*}

![Graph showing mean platelet levels reported in ARIEL3 for patients treated with Rubraca and Placebo.]

- Platelet levels decreased between Cycles 1 and 2 but stabilized thereafter and did not decrease further with additional cycles of treatment\textsuperscript{3}
- Thrombocytopenia/low or decreased platelets led to dose discontinuations in 10/372 patients (3%)\textsuperscript{1}

Please see additional Select Important Safety Information throughout this brochure.

Monitoring and modification recommendations

Guidance for patients with hematologic toxicities

The following guidance was established in ARIEL3 for patients with hematologic toxicities\textsuperscript{1,4}:

**ARIEL3 Monitoring and Dose Modification Recommendations**

<table>
<thead>
<tr>
<th>Grade 2 hematologic toxicities</th>
<th>Consider concomitant medications and/or supportive care</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• If toxicity not adequately controlled, withhold treatment and/or dose reduce</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grade 3 or 4 hematologic toxicities</th>
<th>Withhold treatment and monitor blood counts weekly until resolves to ≤Grade 1 OR Dose reduce and monitor blood counts weekly until resolves to ≤Grade 1</th>
</tr>
</thead>
</table>

- If MDS/AML is suspected, refer patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics\textsuperscript{1}
- If MDS/AML is confirmed, discontinue Rubraca\textsuperscript{1}

SELECT IMPORTANT SAFETY INFORMATION (continued)

Because of the potential for serious adverse reactions in breast-fed children from Rubraca (rucaparib) tablets, advise lactating women not to breastfeed during treatment with Rubraca and for 2 weeks after the last dose.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1-844-258-7662.

*Horizontal dotted lines in graph represent the upper and lower limits of normal.\textsuperscript{3}
*Cycle=28 days. With the exception of Cycle 1, each number on the x axis represents Day 1 of that cycle.\textsuperscript{1,2}
*Hematopoietic growth factors were administered according to institutional guidelines.\textsuperscript{4}

AML=Acute Myeloid Leukemia; MDS=Myelodysplastic Syndrome.
Dose Adjustments for Patients With Hepatic Impairment

- **Mild hepatic impairment**
  - Total bilirubin ≤ULN and AST >ULN, or total bilirubin between 1.0-1.5 x ULN and any AST
  - No adjustment to the starting dose is recommended

- **Moderate to severe hepatic impairment**
  - Total bilirubin >1.5 x ULN
  - No recommendation for starting dose adjustment available due to lack of data

Dose Adjustments for Patients With Renal Impairment

- **Mild to moderate renal impairment**
  - Baseline creatinine clearance (CLcr) between 30 and 89 mL/min, as estimated by the Cockcroft-Gault method
  - No starting dose adjustment is recommended

- **CLcr <30 mL/min or patients on dialysis**
  - No recommendation for starting dose adjustment available due to lack of data

Effect of rucaparib on cytochrome P450 (CYP) substrates

- Co-administration of rucaparib can increase the systemic exposure of CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates, which may increase the risk of toxicities of these drugs
- Adjust dosage of CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates, if clinically indicated
- If co-administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratios (INR) monitoring

Effects of other drugs on rucaparib

- In a population pharmacokinetic analysis, co-administration with proton pump inhibitors had no clinically significant effect on steady-state concentrations of rucaparib

Effect of rucaparib on other drugs

- A single dose of the following drugs was administered before and following rucaparib 600 mg twice daily for 7 days. The C\text{max} of each co-administered drug was ≤1.13-fold, and the AUC changed as follows:
  - Caffeine (CYP1A2): caffeine AUC increased by 2.55-fold
  - Midazolam (CYP3A4): midazolam AUC increased by 1.38-fold
  - Warfarin (CYP2C9): warfarin AUC increased by 1.49-fold
  - Omeprazole (CYP2C19): omeprazole AUC increased by 1.55-fold
  - Digoxin (P-glycoprotein): digoxin AUC increased by 1.20-fold

Adverse reactions were managed with dose interruptions, reductions or discontinuations

- **Discontinued treatment due to adverse reactions vs 2% with placebo**
  - Adverse reactions most frequently leading to discontinuation of treatment with Rubraca were anemia (3%), thrombocytopenia (3%), and nausea (3%)

- **Required dose reduction due to adverse reactions, vs 4% with placebo**
  - Most frequent adverse reactions leading to dose reduction were anemia (12%), thrombocytopenia (11%), and increased ALT/AST (11%)

- **Required dose interruption due to adverse reactions vs 10% with placebo**
  - Most frequent adverse reactions leading to dose interruption were thrombocytopenia (17%), anemia (14%), and increased ALT/AST (11%)

Please see Select Important Safety Information throughout this brochure.
### CTCAE definitions for some common adverse events

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alanine aminotransferase increased</strong>: A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase in the blood specimen.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;ULN - 3.0 x ULN</td>
<td>&gt;3.0 - 5.0 x ULN</td>
<td>&gt;5.0 - 20.0 x ULN</td>
<td>&gt;20.0 x ULN</td>
</tr>
</tbody>
</table>

| **Aspartate aminotransferase increased**: A finding based on laboratory results that indicate an increase in the level of aspartate aminotransferase in a blood specimen. | | | |
| >ULN - 3.0 x ULN | >3.0 - 5.0 x ULN | >5.0 - 20.0 x ULN | >20.0 x ULN |

| **Creatinine increased**: A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen. | | | |
| >1 - 1.5 x baseline; >ULN - 1.5 x ULN | >1.5 - 3.0 x baseline; >ULN - 3.0 x ULN | >3.0 x baseline; >6.0 x ULN | >6.0 x ULN |

| **Anemia**: A reduction of hemoglobin in 100 mL of blood with symptoms including pallor of the skin and mucous membranes, shortness of breath, heart palpitations, soft systolic murmurs, lethargy, and fatigability. | | | |
| Hgb <LLN - 10.0 g/dL; <LLN - 6.2 mmol/L; <LLN - 100 g/L | Hgb <10.0 - 8.0 g/dL; <6.2 - 4.9 mmol/L; <100 - 80 g/L | Hgb <8.0 g/dL; <4.9 mmol/L; <80 g/L; transfusion indicated | Life-threatening consequences; urgent intervention indicated |

| **Platelet count decreased**: A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen. | | | |
| <LLN - 75,000/mm³; <LLN - 75.0 x 10e9/L | <75,000 - 50,000/mm³; <75.0 - 50.0 x 10e9/L | <50,000 - 25,000/mm³; <50.0 - 25.0 x 10e9/L | <25,000/mm³; <25.0 x 10e9/L |

---

**CTCAE definitions for some common adverse events (cont’d)**

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nausea</strong>: A queasy feeling and/or the urge to vomit.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Experiencing a loss of appetite without changing eating habits</td>
<td>Decreased oral intake without significant weight loss, dehydration, or malnutrition</td>
<td>Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated</td>
<td></td>
</tr>
</tbody>
</table>

| **Diarrhea**: Frequent and watery bowel movements. | | | |
| Increase of 4-6 stools per day over baseline; moderate increase in ostomy output | Increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output; limiting self-care ADL | Life-threatening consequences; urgent intervention indicated | |

| **Fatigue**: Generalized weakness and pronounced inability to summon sufficient energy to accomplish activities. | | | |
| Fatigue that is relieved by rest | Fatigue that is not relieved by rest, which limits age-appropriate instrumental ADL | Fatigue that is not relieved by rest, limiting self-care ADL | |

| **Other metabolism and nutrition disorders (eg, decreased appetite)** | | | |
| Asymptomatic or mild symptoms: clinical or diagnostic observations only, intervention not indicated | Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL | Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; disabling; limiting self-care ADL | Life-threatening; urgent intervention indicated |

**In clinical trials with Rubraca® (rucaparib) tablets, adverse reactions were evaluated for severity based on the NCI CTCAE v4.03.**

**Grade 1=Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.**

**Grade 2= Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.**

**Grade 3=Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.**

**Grade 4=Life-threatening consequences; urgent intervention indicated.**

ADL=activities of daily living; Hgb=hemoglobin; LLN=lower limit of normal; TPN=total parenteral nutrition.

---

*Please see full Prescribing Information in the pocket and Select Important Safety Information throughout this brochure.*
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use RUBRACA safely and effectively. See full prescribing information for RUBRACA.

RUBRACA® (rucaparib) tablets, for oral use
Initial U.S. Approval: 2016

-----------RECENT MAJOR CHANGES-----------
Indications and Usage (1.1, 1.2) 04/2018
Dosing and Administration (2.3) 04/2018
Warnings and Precautions (5.1) 04/2018

-----------INDICATIONS AND USAGE-----------
RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
• for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. (1.1)
• for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. (1.2, 2.3)

-----------DOSAGE AND ADMINISTRATION-----------
• Recommended dose is 600 mg orally twice daily with or without food. (2.1)
• Continue treatment until disease progression or unacceptable toxicity. (2.1)
• For adverse reactions, consider interruption of treatment or dose reduction. (2.2)

-----------DOSAGE FORMS AND STRENGTHS-----------
Tablets: 200 mg, 250 mg, and 300 mg (3)

-----------CONTRAINDICATIONS-----------
None. (4)

-----------WARNINGS AND PRECAUTIONS-----------
• Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): MDS/AML occurred in patients exposed to RUBRACA, and some cases were fatal. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS/AML is confirmed. (5.1)
• Embryo-Fetal Toxicity: RUBRACA can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.2, 8.1, 8.3)

-----------ADVERSE REACTIONS-----------
• Most common adverse reactions (≥ 20%) were nausea, fatigue (including asthenia), vomiting, anemia, dysgeusia, AST/ALT elevation, constipation, decreased appetite, diarrhea, thrombocytopenia, neutropenia, stomatitis, nasopharyngitis/URI, rash, abdominal pain/distention, and dyspnea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Clovis Oncology, Inc. at 1-844-258-7662 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-----------DRUG INTERACTIONS-----------
• CYP1A2, CYP3A, CYP2C9, and CYP2C19 substrates: Adjust dosage if clinically indicated. (7)

-----------USE IN SPECIFIC POPULATIONS-----------
• Lactation: Advise women not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 04/2018

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
  1.1 Maintenance Treatment of Recurrent Ovarian Cancer
  1.2 Treatment of BRCA-mutated Ovarian Cancer After 2 or More Chemotherapies

2 DOSAGE AND ADMINISTRATION
  2.1 Recommended Dose
  2.2 Dose Modifications for Adverse Reactions
  2.3 Patient Selection for Treatment of BRCA-mutated Ovarian Cancer

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS
  5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia
  5.2 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS
  6.1 Clinical Trials Experience

7 DRUG INTERACTIONS
  7.1 Effect of Rucaparib on Cytochrome p450 (CYP) Substrates

8 USE IN SPECIFIC POPULATIONS
  8.1 Pregnancy
  8.2 Lactation
  8.3 Females and Males of Reproductive Potential

8.4 Pediatric Use
8.5 Geriatric Use
8.6 Hepatic Impairment
8.7 Renal Impairment

10 OVERDOSAGE
11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
  12.1 Mechanism of Action
  12.2 Pharmacodynamics
  12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
  13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES
  14.1 Maintenance Treatment of Recurrent Ovarian Cancer
  14.2 Treatment of BRCA-mutated Ovarian Cancer After 2 or More Chemotherapies

16 HOW SUPPLIED/STORAGE AND HANDLING
  16.1 How Supplied
  16.2 Storage

17 PATIENT COUNSELING INFORMATION
*Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Maintenance Treatment of Recurrent Ovarian Cancer

Rubraca is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy [see Dosage and Administration (2.1)].

1.2 Treatment of BRCA-mutated Ovarian Cancer After 2 or More Chemotherapies

Rubraca is indicated for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca [see Dosage and Administration (2.1)].

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

The recommended dose of Rubraca is 600 mg (two 300 mg tablets) taken orally twice daily with or without food. Continue treatment until disease progression or unacceptable toxicity.

If a patient misses a dose of Rubraca, instruct the patient to take the next dose at its scheduled time. Vomited doses should not be replaced.

2.2 Dose Modifications for Adverse Reactions

To manage adverse reactions, consider interruption of treatment or dose reduction. Recommended dose reductions are indicated in Table 1.

Table 1. Recommended Dose Adjustments

<table>
<thead>
<tr>
<th>Dose Reduction</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting Dose</td>
<td>600 mg twice daily (two 300 mg tablets)</td>
</tr>
<tr>
<td>First Dose Reduction</td>
<td>500 mg twice daily (two 250 mg tablets)</td>
</tr>
<tr>
<td>Second Dose Reduction</td>
<td>400 mg twice daily (two 200 mg tablets)</td>
</tr>
<tr>
<td>Third Dose Reduction</td>
<td>300 mg twice daily (one 300 mg tablet)</td>
</tr>
</tbody>
</table>

2.3 Patient Selection for Treatment of BRCA-mutated Ovarian Cancer

Select patients for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with Rubraca based on the presence of a deleterious BRCA mutation (germline and/or somatic) [see Indications and Usage (1.2) and Clinical Studies (14.2)]. Information on the FDA-approved test for the detection of a tumor BRCA mutation in patients with ovarian cancer is available at: http://www.fda.gov/CompanionDiagnostics.
3 DOSAGE FORMS AND STRENGTHS

- Tablets (200 mg): blue, round, immediate-release, film-coated, debossed with “C2”.
- Tablets (250 mg): white, diamond, immediate-release, film-coated, debossed with “C25”.
- Tablets (300 mg): yellow, oval, immediate-release, film-coated, debossed with “C3”.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia

Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) occur uncommonly in patients treated with Rubraca, and are potentially fatal adverse reactions. In approximately 1100 treated patients, MDS/AML occurred in 12 patients (1.1%), including those in long term follow-up. Of these, 5 occurred during treatment or during the 28 day safety follow-up (0.5%). The duration of Rubraca treatment prior to the diagnosis of MDS/AML ranged from 1 month to approximately 28 months. The cases were typical of secondary MDS/cancer therapy-related AML; in all cases, patients had received previous platinum-containing chemotherapy regimens and/or other DNA damaging agents.

Do not start Rubraca until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood counts for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities (> 4 weeks), interrupt Rubraca or reduce dose according to Table 1 [see Dosage and Administration (2.2)] and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks or if MDS/AML is suspected, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue Rubraca.

5.2 Embryo-Fetal Toxicity

Rubraca can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings from animal studies. In an animal reproduction study, administration of rucaparib to pregnant rats during the period of organogenesis resulted in embryo-fetal death at exposures that were 0.04 times the AUC0-24h in patients receiving the recommended human dose of 600 mg twice daily. Apprise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Rubraca [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed elsewhere in the labeling:

- Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions (5.1)].

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

**Maintenance Treatment of Recurrent Ovarian Cancer**

The safety of Rubraca for the maintenance treatment of patients with epithelial ovarian, fallopian tube, or primary
peritoneal cancer was investigated in ARIEL3, a randomized (2:1), double-blind, placebo-controlled study in which 561 patients received either Rubraca 600 mg BID (n=372) or placebo (n=189) until disease progression or unacceptable toxicity. The median duration of study treatment was 8.3 months (range: < 1 month to 35 months) for patients who received Rubraca and 5.5 months for patients who received placebo.

Dose interruptions due to an adverse reaction of any grade occurred in 65% of patients receiving Rubraca and 10% of those receiving placebo; dose reductions due to an adverse reaction occurred in 55% of Rubraca patients and 4% of placebo patients. The most frequent adverse reactions leading to dose interruption or dose reduction of Rubraca were thrombocytopenia (18%), anemia (17%), nausea (15%), and fatigue/asthenia (13%). Discontinuation due to adverse reactions occurred in 15% of Rubraca patients and 2% of placebo patients. Specific adverse reactions that most frequently led to discontinuation in patients treated with Rubraca were anemia (3%), thrombocytopenia (3%) and nausea (3%).

Table 2. Adverse Reactions in ARIEL3 Occurring in ≥ 20% of Patients

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Rubraca N=372</th>
<th>Placebo N=189</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grades* 1-4 %</td>
<td>Grades 3-4 %</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>76</td>
<td>4</td>
</tr>
<tr>
<td>Abdominal pain/distention</td>
<td>46</td>
<td>3</td>
</tr>
<tr>
<td>Constipation</td>
<td>37</td>
<td>2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>37</td>
<td>4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>32</td>
<td>0.5</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>28</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue/asthenia</td>
<td>73</td>
<td>7</td>
</tr>
<tr>
<td>Skin and Subcutaneous Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>43</td>
<td>1</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST/ALT elevation</td>
<td>38</td>
<td>11</td>
</tr>
<tr>
<td>Blood and Lymphatic System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>39</td>
<td>21</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>29</td>
<td>5</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>20</td>
<td>8</td>
</tr>
<tr>
<td>Respiratory, Thoracic, and Mediastinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis/Upper respiratory tract infection b</td>
<td>29</td>
<td>0.3</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>23</td>
<td>1</td>
</tr>
</tbody>
</table>

* National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03)

b Consists of grouped related terms that reflect the medical concept of the adverse reaction

Adverse reactions occurring < 20% of patients treated with Rubraca include headache (18%), dizziness (19%), dyspepsia (19%), insomnia (15%), dyspnea (17%), pyrexia (13%), peripheral edema (11%), and depression (11%).
Table 3. Laboratory Abnormalities in ARIEL3 Occurring in $\geq 25\%$ of Patients

<table>
<thead>
<tr>
<th>Laboratory Parametera</th>
<th>Rubraca N=372</th>
<th>Placebo N=189</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade 1-4 %</td>
<td>Grade 3-4 %</td>
</tr>
<tr>
<td>Chemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in creatinine</td>
<td>98</td>
<td>0.3</td>
</tr>
<tr>
<td>Increase in cholesterol</td>
<td>84</td>
<td>4</td>
</tr>
<tr>
<td>Increase in ALT</td>
<td>73</td>
<td>7</td>
</tr>
<tr>
<td>Increase in AST</td>
<td>61</td>
<td>1</td>
</tr>
<tr>
<td>Increase in Alkaline Phosphatase</td>
<td>37</td>
<td>0.3</td>
</tr>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decrease in hemoglobin</td>
<td>88</td>
<td>13</td>
</tr>
<tr>
<td>Decrease in platelets</td>
<td>44</td>
<td>2</td>
</tr>
<tr>
<td>Decrease in leukocytes</td>
<td>44</td>
<td>3</td>
</tr>
<tr>
<td>Decrease in neutrophils</td>
<td>38</td>
<td>6</td>
</tr>
<tr>
<td>Decrease in lymphocytes</td>
<td>29</td>
<td>5</td>
</tr>
</tbody>
</table>

a Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1.

Treatment of BRCA-mutated Recurrent Ovarian Cancer After 2 or More Chemotherapies

Rubraca 600 mg twice daily as monotherapy has also been studied in 377 patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have progressed after 2 or more prior chemotherapies in two open-label, single arm trials. In these patients, the median age was 62 years (range: 31 to 86), 100% had an ECOG performance status of 0 or 1, 38% had BRCA-mutated ovarian cancer, 45% had received 3 or more prior lines of chemotherapy, and the median time since ovarian cancer diagnosis was 43 months (range: 6 to 197).
### Table 4. Adverse Reactions Reported in ≥ 20% of Patients with Ovarian Cancer After ≥ 2 Chemotherapies Treated with Rubraca in Study 10 and ARIEL2

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>All Ovarian Cancer Patients (N = 377)%</th>
<th>Gradesa 1-4</th>
<th>Grades 3-4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastrointestinal Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>77</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>46</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>40</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>34</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>32</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>General Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenia/Fatigue</td>
<td>77</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td><strong>Blood and Lymphatic System Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>44</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>21</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>39</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism and Nutrition Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>39</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, Thoracic, and Mediastinal Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>21</td>
<td>0.5</td>
<td></td>
</tr>
</tbody>
</table>

*a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03)

The following adverse reactions have been identified in < 20% of the 377 patients treated with Rubraca 600 mg twice daily: dizziness (17%), neutropenia (15%), rash (includes rash, rash erythematous, rash maculopapular and dermatitis) (13%), pyrexia (11%), photosensitivity reaction (10%), pruritus (includes pruritus and pruritus generalized) (9%), Palmar-plantar erythrodysoestheisa syndrome (2%), and febrile neutropenia (1%).

### Table 5. Laboratory Abnormalities Reported in ≥ 35% of Patients with Ovarian Cancer After ≥ 2 Chemotherapies Treated with Rubraca in Study 10 and ARIEL2

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>All Patients with Ovarian Cancer (N = 377)%</th>
<th>Grade 1-4a</th>
<th>Grade 3-4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Chemistry</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in creatinine</td>
<td>92</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Increase in ALTb</td>
<td>74</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Increase in ASTb</td>
<td>73</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Increase in cholesterol</td>
<td>40</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>Hematologic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decrease in hemoglobin</td>
<td>67</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Decrease in lymphocytes</td>
<td>45</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Decrease in platelets</td>
<td>39</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Decrease in absolute neutrophil count</td>
<td>35</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

*a At least one worsening shift in CTCAE grade and by maximum shift from baseline.
b Increase in ALT/AST led to treatment discontinuation in 0.3% of patients (1/377).
7 DRUG INTERACTIONS

7.1 Effect of Rucaparib on Cytochrome p450 (CYP) Substrates

Co-administration of rucaparib can increase the systemic exposure of CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates [see Clinical Pharmacology (12.3)], which may increase the risk of toxicities of these drugs.

Adjust dosage of CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates, if clinically indicated. If co-administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on findings from animal studies and its mechanism of action, Rubraca can cause fetal harm when administered to pregnant women. There are no available data in pregnant women to inform the drug-associated risk. In an animal reproduction study, administration of rucaparib to pregnant rats during organogenesis resulted in embryo-fetal death at maternal exposures that were 0.04 times the AUC\(_{0-24h}\) in patients receiving the recommended dose of 600 mg twice daily [see Data]. Apprise pregnant women of the potential risk to a fetus.

The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

In a dose range-finding embryo-fetal development study, pregnant rats received oral doses of 50, 150, 500, or 1000 mg/kg/day of rucaparib during the period of organogenesis. Post-implantation loss (100% early resorptions) was observed in all animals at doses greater than or equal to 50 mg/kg/day (with maternal systemic exposures approximately 0.04 times the human exposure at the recommended dose based on AUC\(_{0-24h}\)).

8.2 Lactation

Risk Summary

There is no information regarding the presence of rucaparib in human milk, or on its effects on milk production or the breast-fed child. Because of the potential for serious adverse reactions in breast-fed children from Rubraca, advise lactating women not to breastfeed during treatment with Rubraca and for 2 weeks following the last dose.

8.3 Females and Males of Reproductive Potential

Pregnancy Testing

Pregnancy testing is recommended for females of reproductive potential prior to initiating Rubraca.
Contraception

Females

Rubraca can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Rubraca.

8.4 Pediatric Use

The safety and effectiveness of Rubraca in pediatric patients have not been established.

8.5 Geriatric Use

In clinical studies 40% (297/749) of patients with ovarian cancer treated with Rubraca were 65 years of age or older and 9% (65/749) were 75 years or older. Grade 3-4 adverse reactions occurred in 65% of patients 65 years or older and in 63% of patients 75 years or older. For patients 65 years or older, the most common Grade 3-4 adverse reactions were anemia, fatigue/asthenia, and ALT/AST increase. No major differences in safety were observed between these patients and younger patients for the maintenance treatment of recurrent ovarian cancer or for the treatment of BRCA-mutated ovarian cancer after two or more chemotherapies.

8.6 Hepatic Impairment

No starting dose adjustment is recommended for patients with mild hepatic impairment (total bilirubin less than or equal to upper limit of normal [ULN] and AST greater than ULN, or total bilirubin between 1.0 to 1.5 times ULN and any AST). No recommendation for starting dose adjustment is available for patients with moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN) due to a lack of data [See Clinical Pharmacology (12.3)].

8.7 Renal Impairment

No starting dose adjustment is recommended for patients with mild to moderate renal impairment (baseline creatinine clearance [CLcr] between 30 and 89 mL/min, as estimated by the Cockcroft-Gault method). There is no recommended starting dose for patients with CLcr less than 30 mL/min or patients on dialysis due to a lack of data [See Clinical Pharmacology (12.3)].

10 OVERDOSAGE

There is no specific treatment in the event of Rubraca overdose, and symptoms of overdose are not established. In the event of suspected overdose, physicians should follow general supportive measures and should treat symptomatically.

11 DESCRIPTION

Rucaparib is an inhibitor of the mammalian polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme. The chemical name is 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic acid salt. The chemical formula of rucaparib camsylate is C_{19}H_{18}F_{15}O_{4}•C_{10}H_{16}O_{4}S and the relative molecular mass is 555.67 Daltons.

The chemical structure of rucaparib camsylate is shown below:
Rucaparib camsylate is a white to pale yellow powder; formulated into a tablet for oral use. Rucaparib shows pH-independent low solubility of approximately 1 mg/mL across the physiological pH range.

Rubraca (rucaparib) tablets contain rucaparib camsylate as the active ingredient. Each 200 mg tablet contains 344 mg rucaparib camsylate equivalent to 200 mg rucaparib free base. Each 250 mg tablet contains 430 mg rucaparib camsylate equivalent to 250 mg rucaparib free base. Each 300 mg tablet contains 516 mg rucaparib camsylate equivalent to 300 mg rucaparib free base.

The inactive ingredients in Rubraca tablets include: microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The cosmetic blue film coating for 200 mg tablets, cosmetic white film coating for 250 mg tablets, and cosmetic yellow film coating for 300 mg tablets is Opadry II containing polyvinyl alcohol, titanium dioxide, polyethylene glycol/macrogol, and talc. The coating is colorized as blue using brilliant blue aluminum lake and indigo carmine aluminum lake, or yellow using yellow iron oxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. In vitro studies have shown that rucaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cancer cell death. Increased rucaparib-induced cytotoxicity and anti-tumor activity was observed in tumor cell lines with deficiencies in \textit{BRCA1/2} and other DNA repair genes. Rucaparib has been shown to decrease tumor growth in mouse xenograft models of human cancer with or without deficiencies in \textit{BRCA}.

12.2 Pharmacodynamics

The pharmacodynamic response of rucaparib has not been characterized.

Cardiac Electrophysiology

The effect of multiple doses of Rubraca on QTc interval was evaluated in an open-label single-arm study in 56 patients with solid tumors who were administered continuous doses of Rubraca ranging from 40 mg once daily (0.03 times the approved recommended dose) to 840 mg twice daily (1.4 times the approved recommended dose). The mean QTcF increase from baseline (90% confidence interval [CI]) in population pharmacokinetics estimated 95\textsuperscript{th} percentile \(C_{\text{max}}\) (3019 ng/mL) at steady state of 600 mg rucaparib twice daily was 14.9 msec (11.1-18.7 msec).

12.3 Pharmacokinetics

The pharmacokinetic profile of rucaparib was characterized in patients with cancer. Rucaparib demonstrated linear pharmacokinetics over a dose range from 240 to 840 mg twice daily with time-independence and dose-proportionality. The mean steady-state rucaparib \(C_{\text{max}}\) was 1940 ng/mL (54\% coefficient of variation [CV]) and AUC\textsubscript{0-12h} was 16900 h·ng/mL (54\% CV) at the approved recommended dose. Accumulation was 3.5 to 6.2 fold.
Absorption

The median T_{max} was 1.9 hours at the approved recommended dose. The mean absolute bioavailability of rucaparib immediate-release tablet was 36% with a range from 30% to 45%.

Following a high-fat meal, the C_{max} was increased by 20% and AUC_{0-24h} was increased by 38%, and T_{max} was delayed by 2.5 hours, as compared to dosing under fasted conditions [see Dosage and Administration (2.2)].

Distribution

Rucaparib had a steady-state volume of distribution of 113 L to 262 L following a single intravenous dose of 12 mg to 40 mg rucaparib.

In vitro, the protein binding of rucaparib was 70% in human plasma at therapeutic concentrations. Rucaparib preferentially distributed to red blood cells with a blood-to-plasma concentration ratio of 1.83.

Elimination

The mean terminal T_{1/2} of rucaparib was 17 to 19 hours, following a single oral dose of 600 mg rucaparib. The apparent clearance ranged from 15.3 to 79.2 L/hour, following rucaparib 600 mg twice daily. The clearance ranged from 13.9 to 18.4 L/hour, following a single intravenous dose of rucaparib 12 mg to 40 mg.

Metabolism

In vitro, rucaparib had a low metabolic turnover rate and was metabolized primarily by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.

Specific Populations

Age, Race, and Body Weight

Based on population pharmacokinetic analyses, age, race, and body weight did not have a clinically meaningful effect on rucaparib exposure.

Renal Impairment

In patients who received Rubraca 600 mg twice daily, those with mild renal impairment (N=148; baseline CLcr between 60 and 89 mL/min, as estimated by the Cockcroft-Gault method) and those with moderate renal impairment (N=72; CLcr between 30 and 59 mL/min) showed approximately 15% and 32% higher steady-state AUC, respectively, compared to patients with normal renal function (N=143; CLcr greater than or equal to 90 mL/min). The pharmacokinetic characteristics of rucaparib in patients with CLcr less than 30 mL/min or patients on dialysis are unknown.

Hepatic Impairment

Based on population pharmacokinetic analyses, no apparent pharmacokinetic difference was observed in 34 patients with mild hepatic impairment (total bilirubin less than or equal to ULN and AST greater than ULN, or total bilirubin between 1.0 to 1.5 times ULN and any AST) who received Rubraca 600 mg twice daily as compared to patients with normal hepatic function (N=337). The pharmacokinetic characteristics of rucaparib in patients with moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN) are unknown.

CYP Enzyme Polymorphism

Based on population pharmacokinetic analyses, steady-state concentrations following rucaparib 600 mg twice daily did not differ significantly across CYP2D6 or CYP1A2 genotype subgroups.
Drug Interaction Studies

Effect of Rucaparib on Other Drugs

Clinical Studies

A single dose of the following drugs was administered before and following rucaparib 600 mg twice daily for 7 days. The $C_{max}$ of each co-administered drug was $\leq 1.13$-fold, and the AUC changed as follows:

- Caffeine (CYP1A2): caffeine AUC increased by 2.55-fold
- Midazolam (CYP3A4): midazolam AUC increased by 1.38-fold
- Warfarin (CYP2C9): warfarin AUC increased by 1.49-fold
- Omeprazole (CYP2C19): omeprazole AUC increased by 1.55-fold
- Digoxin (P-glycoprotein): digoxin AUC increased by 1.20-fold

In Vitro Studies

Rucaparib inhibited CYP2C8, CYP2D6, and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). Rucaparib induced CYP1A2, and down regulated CYP3A4 and CYP2B6.

Rucaparib inhibited the P-glycoprotein (P-gp) efflux transporter, breast cancer resistance protein (BCRP), organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3), organic anion transporters 1 and 3 (OAT1 and OAT3), multidrug and toxin extrusion 1 and 2-k (MATE1 and MATE2-K), organic cation transporters 1 and 2 (OCT1 and OCT2), and multidrug resistance-associated protein 4 (MRP4). No apparent inhibition was observed for MRP2, MRP3, or BSEP.

Effects of Other Drugs on Rucaparib

Clinical Studies

In a population pharmacokinetic (PPK) analysis, co-administration with proton pump inhibitors had no clinically significant effect on steady-state concentrations of rucaparib.

In Vitro Studies

Rucaparib was a substrate of P-gp and BCRP; however, rucaparib was not a substrate of OATP1B1, OATP1B3, OAT1, OAT3, and OCT2.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity studies have not been conducted with rucaparib.

Rucaparib was clastogenic in an in vitro chromosomal aberration assay in cultured human lymphocytes. The clastogenic response in mitotically-stimulated cells was anticipated based on the mechanism of action of rucaparib and indicates potential genotoxicity in humans. Rucaparib was not mutagenic in a bacterial reverse mutation (Ames) test.

Fertility studies with rucaparib have not been conducted. In 3-month repeat-dose general toxicology studies, rucaparib had no effects on male and female reproductive organs at doses up to 100 mg/kg/day and 20 mg/kg/day in rats and dogs, respectively. These dose levels resulted in systemic exposures of approximately 0.3 and 0.09 times the human exposure (AUC$_{0-24h}$), respectively, at the recommended dose.
14 CLINICAL STUDIES

14.1 Maintenance Treatment of Recurrent Ovarian Cancer

The efficacy of Rubraca was investigated in ARIEL3 (NCT01968213), a double-blind, multicenter clinical trial in which 564 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in response to platinum-based chemotherapy were randomized (2:1) to receive Rubraca tablets 600 mg orally twice daily (n=375) or placebo (n=189). Treatment was continued until disease progression or unacceptable toxicity. All patients had achieved a response (complete or partial) to their most recent platinum-based chemotherapy. Randomization was stratified by best response to last platinum (complete or partial), time to progression following the penultimate platinum therapy (6 to ≤ 12 months and > 12 months), and tumor biomarker status. The major efficacy outcome was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (v1.1).

The median age was 61 years (range: 39 to 84) for patients receiving Rubraca and 62 years (range: 36 to 85) for those on placebo; the majority were White (80%); and 100% had an ECOG performance status of 0 or 1. All patients had received at least two prior platinum-based chemotherapies (range: 2 to 7). A total of 34% of patients were in complete response (CR) to their most recent therapy. The progression-free interval to penultimate platinum was 6-12 months in 40% of patients and > 12 months in 60%. Prior bevacizumab therapy was reported for 22% of patients who received Rubraca and 23% of patients who received placebo. Measurable disease was present at baseline in 37% of patients.

Tumor tissue samples were tested using a clinical trial assay (CTA) (N=564), and the FoundationFocus™ CDx BRCA LOH test (n=518). Of the samples evaluated with both tests, homologous recombination deficiency (HRD) positive status (as defined by the presence of a deleterious BRCA mutation or high genomic loss of heterozygosity) was confirmed by the FoundationFocus™ CDx BRCA LOH test for 94% (313/332) of HRD-positive patients determined by the CTA; and of these, tumor BRCA (tBRCA) mutant status was confirmed by the FoundationFocus™ CDx BRCA LOH test for 99% (177/178) of tBRCA-positive patients determined by the CTA. Blood samples for 94% (186/196) of the tBRCA patients were evaluated using a central blood germline BRCA test. Based on these results, 70% (130/186) of the tBRCA patients had a germline BRCA mutation and 30% (56/186) had a somatic BRCA mutation.

ARIEL3 demonstrated a statistically significant improvement in PFS for patients randomized to Rubraca as compared with placebo in all patients, and in the HRD and tBRCA subgroups. Results from a blinded independent radiology review were consistent. At the time of the analysis of PFS, overall survival (OS) data were not mature (with 22% of events). Efficacy results are summarized in Table 6 and Figures 1, 2, and 3.
Table 6. Efficacy Results - ARIEL3 (Investigator Assessment)

<table>
<thead>
<tr>
<th></th>
<th>Rubraca</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Patients</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients, N</td>
<td>375</td>
<td>189</td>
</tr>
<tr>
<td>PFS events, n (%)</td>
<td>234 (62%)</td>
<td>167 (88%)</td>
</tr>
<tr>
<td>PFS, median in months</td>
<td>10.8</td>
<td>5.4</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.36 (0.30, 0.45)</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>&lt; 0.0001</td>
<td></td>
</tr>
<tr>
<td><strong>HRD Group</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients, N</td>
<td>236</td>
<td>118</td>
</tr>
<tr>
<td>PFS events, n (%)</td>
<td>134 (57%)</td>
<td>101 (86%)</td>
</tr>
<tr>
<td>PFS, median in months</td>
<td>13.6</td>
<td>5.4</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.32 (0.24, 0.42)</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>&lt; 0.0001</td>
<td></td>
</tr>
<tr>
<td><strong>tBRCA Group</strong>&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients, N</td>
<td>130</td>
<td>66</td>
</tr>
<tr>
<td>PFS events, n (%)</td>
<td>67 (52%)</td>
<td>56 (85%)</td>
</tr>
<tr>
<td>PFS, median in months</td>
<td>16.6</td>
<td>5.4</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.23 (0.16, 0.34)</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>&lt; 0.0001</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> All randomized patients.

<sup>b</sup> HRD includes all patients with a deleterious germline or somatic BRCA mutation or high genomic loss of heterozygosity, as determined by the CTA.

<sup>c</sup> tBRCA includes all patients with a deleterious germline or somatic BRCA mutation, as determined by the CTA.
Figure 1. Kaplan-Meier Curves of Progression-Free Survival in ARIEL3 as Assessed by Investigator: All Patients

<table>
<thead>
<tr>
<th></th>
<th>Median (months)</th>
<th>95% CI</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rubraca</td>
<td>10.8</td>
<td>8.3–11.4</td>
<td>0–33+</td>
</tr>
<tr>
<td>Placebo</td>
<td>5.4</td>
<td>5.3–5.5</td>
<td>0–33+</td>
</tr>
</tbody>
</table>

At risk (events)
Rubraca    375 (0) 279 (65) 207 (130) 128 (186) 89 (205) 44 (222) 26 (226) 6 (234) 3 (234) 0 (234)
Placebo    189 (0) 115 (65) 53 (124) 13 (160) 10 (162) 3 (166) 2 (167) 1 (167) 1 (167) 0 (167)

Figure 2. Kaplan-Meier Curves of Progression-Free Survival in ARIEL3 as Assessed by Investigator: HRD Group

<table>
<thead>
<tr>
<th></th>
<th>Median (months)</th>
<th>95% CI</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rubraca</td>
<td>13.6</td>
<td>10.9–16.2</td>
<td>0–33+</td>
</tr>
<tr>
<td>Placebo</td>
<td>5.4</td>
<td>5.1–5.6</td>
<td>0–25+</td>
</tr>
</tbody>
</table>

At risk (events)
Rubraca    236 (0) 190 (29) 149 (67) 96 (104) 70 (116) 36 (126) 21 (129) 6 (134) 3 (134) 0 (134)
Placebo    118 (0) 71 (40) 32 (76) 11 (95) 9 (96) 2 (100) 1 (101) 0 (101)
14.2 Treatment of BRCA-mutated Ovarian Cancer After 2 or More Chemotherapies

The efficacy of Rubraca was investigated in 106 patients in two multicenter, single-arm, open-label clinical trials, Study 10 (NCT01482715) and ARIEL2 (NCT01891344), in patients with advanced BRCA-mutant ovarian cancer who had progressed after 2 or more prior chemotherapies. All 106 patients received Rubraca 600 mg orally twice daily as monotherapy until disease progression or unacceptable toxicity. Objective response rate (ORR) and duration of response (DOR) were assessed by the investigator and IRR according to RECIST v1.1.

The median age of the patients was 59 years (range: 33 to 84), the majority were White (78%), and 100% had an ECOG performance status of 0 or 1. All patients had received at least two prior platinum-based chemotherapies and 43% had received 3 or more prior lines of platinum-based chemotherapy. There were 18/106 patients (17%) who had deleterious BRCA mutations detected in tumor tissue and not in whole blood specimens. Tumor BRCA mutation status was verified retrospectively in 96% (64/67) of the patients for whom a tumor tissue sample was available by the companion diagnostic FoundationFocus™ CDxBRCA test, which is FDA approved for selection of patients for Rubraca treatment.

Efficacy results are summarized in Table 7.

### Table 7. Overall Response and Duration of Response in Patients with BRCA-mutant Ovarian Cancer Who Received 2 or More Chemotherapies in Study 10 and ARIEL2

<table>
<thead>
<tr>
<th></th>
<th>Investigator-assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=106</td>
</tr>
<tr>
<td>Objective Response Rate (95% CI)</td>
<td>54% (44, 64)</td>
</tr>
<tr>
<td>Complete Response</td>
<td>9%</td>
</tr>
<tr>
<td>Partial Response</td>
<td>45%</td>
</tr>
<tr>
<td>Median DOR in months (95% CI)</td>
<td>9.2 (6.6, 11.6)</td>
</tr>
</tbody>
</table>
Response assessment by independent radiology review was 42% (95% CI [32, 52]), with a median DOR of 6.7 months (95% CI [5.5, 11.1]). Investigator-assessed ORR was 66% (52/79; 95% CI [54, 76]) in platinum-sensitive patients, 25% (5/20; 95% CI [9, 49]) in platinum-resistant patients, and 0% (0/7; 95% CI [0, 41]) in platinum-refractory patients. ORR was similar for patients with a BRCA1 gene mutation or BRCA2 gene mutation.

16  HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Rubraca is available as 200 mg, 250 mg, and 300 mg tablets.

200 mg Tablets:
- Blue, round, and debossed with “C2” on one side
- Supplied in bottles of 60 tablets (NDC: 69660-201-91)

250 mg Tablets:
- White, diamond, and debossed with “C25” on one side
- Supplied in bottles of 60 tablets (NDC: 69660-202-91)

300 mg Tablets:
- Yellow, oval, and debossed with “C3” on one side
- Supplied in bottles of 60 tablets (NDC: 69660-203-91)

16.2 Storage

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

17  PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

MDS/AML: Advise patients to contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions. These may be signs of hematological toxicity or a more serious uncommon bone marrow problem called ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukemia’ (AML) which have been reported in patients treated with Rubraca [see Warnings and Precautions (5.1)].

Embryo-Fetal Toxicity: Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after receiving the last dose of Rubraca [see Warnings and Precautions (5.2) and Use in Specific Populations (8.1, 8.3)].

Photosensitivity: Advise patients to use appropriate sun protection due to the increased susceptibility to sunburn while taking Rubraca [see Adverse Drug Reactions (6.1)].

Lactation: Advise females not to breastfeed during treatment and for 2 weeks after the last dose of Rubraca [see Use in Specific Populations (8.2)].

Dosing Instructions: Instruct patients to take Rubraca orally twice daily with or without food. Doses should be taken approximately 12 hours apart. Advise patients that if a dose of Rubraca is missed or if the patient vomits after taking a dose of Rubraca, patients should not take an extra dose, but take the next dose at the regular time [see Dosage and Administration (2.1)].
What is the most important information I should know about Rubraca?

Rubraca may cause serious side effects including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

Symptoms of low blood cell counts are common during treatment with Rubraca, but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with Rubraca:

- weakness
- weight loss
- fever
- frequent infections
- blood in urine or stool
- shortness of breath
- feeling very tired
- bruising or bleeding more easily

Your healthcare provider will do blood tests to check your blood cell counts:

- before treatment with Rubraca.
- every month during treatment with Rubraca.
- weekly if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

See "What are possible side effects of Rubraca?" for more information about side effects.

What is Rubraca?

Rubraca is a prescription medicine used for:

- the maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy.
- the treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain ‘BRCA’ gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer.

Your healthcare provider will perform a test to make sure Rubraca is right for you.

It is not known if Rubraca is safe and effective in children.

Before you take Rubraca, tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca.
  - If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca.
  - Females who are able to become pregnant should use effective birth control during treatment and for 6 months after the last dose of Rubraca. Talk to your healthcare provider about birth control methods that may be right for you.
  - Tell your healthcare provider right away if you become pregnant.
- are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take Rubraca?

- Take Rubraca exactly as your healthcare provider tells you.
- Your healthcare provider may temporarily stop treatment with Rubraca or change your dose of Rubraca if you have side effects. Do not change your dose or stop taking Rubraca unless your healthcare provider tells you to.
- Take Rubraca 2 times a day. Each dose should be taken about 12 hours apart.
- Take Rubraca with or without food.
• If you miss a dose of Rubraca, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose.
• If you vomit after taking a dose of Rubraca, do not take an extra dose. Take your next dose at your usual time.
• If you take too much Rubraca, call your healthcare provider or go to the nearest emergency room right away.

What should I avoid while taking Rubraca?
Avoid spending time in sunlight. Rubraca can make your skin sensitive to the sun (photosensitivity). You may sunburn more easily during treatment with Rubraca. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the possible side effects of Rubraca?
Rubraca may cause serious side effects.

See “What is the most important information I should know about Rubraca?”
The most common side effects of Rubraca include:
• nausea
• tiredness or weakness
• vomiting
• decrease in hemoglobin (anemia)
• changes in how food tastes
• constipation
• decreased appetite
• diarrhea
• low blood cell counts
• mouth sores
• upper respiratory tract infection
• shortness of breath
• rash
• changes in liver or kidney function blood tests
• stomach (abdomen) pain
• increased cholesterol levels

These are not all of the possible side effects of Rubraca. For more information, ask your healthcare provider or pharmacist.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Rubraca?
• Store Rubraca at room temperature between 68°F to 77°F (20°C to 25°C).

Keep Rubraca and all medicines out of the reach of children.

General information about the safe and effective use of Rubraca
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Rubraca for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about Rubraca.

What are the ingredients in Rubraca?
Active ingredient: rucaparib
Inactive ingredients: microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The film coating contains polyvinyl alcohol, titanium dioxide, polyethylene glycol/macrogol, and talc. The blue film coating contains brilliant blue aluminum lake and indigo carmine aluminum lake. The yellow film coating contains yellow iron oxide.

Distributed by: Clovis Oncology, Inc. Boulder, Colorado 80301
For more information, go to www.Rubraca.com or call 1-844-258-7662.

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: April 2018